Department of Nuclear Medicine, Imperial College Healthcare Trust, London, UK.
Mol Imaging Biol. 2011 Aug;13(4):769-75. doi: 10.1007/s11307-010-0396-8.
We aimed to compare imaging with (123)I-MIBG and (68)Ga-DOTA-TATE in neural crest tumours (NCT) to see if the latter could offer more advantage in detecting extra lesions and have higher sensitivity for malignant lesions.
We retrospectively reviewed 12 patients (M = 10, F = 2; age range 20-71 years) with NCT (phaeochromocytomas = 7, paragangliomas = 4, medullary thyroid cancer = 1) who underwent both (68)Ga-DOTA-TATE positron emission tomography (PET) or PET/computed tomography (CT) and (123)I-MIBG single-photon emission computed tomography within 6 months. Visual assessment of all lesions and measurement of target/non-target (T/N) ratio in selected lesions were performed. Five patients (aged 50 or less) had SDHB screening results correlated with imaging results of both radiopharmaceuticals. All patients had contrast-enhanced CT and/or other cross-sectional imaging.
(68)Ga-DOTA-TATE PET showed tumour lesions in ten out of 12 patients with confirmed disease, while (123)I-MIBG showed lesions in five out of 12 patients. In one patient, both (68)Ga-DOTA-TATE PET and (123)I-MIBG were negative, but CT, magnetic resonance imaging, and 2-deoxy-2-[(18)F]fluoro-D-glucose PET scans identified a lesion in the thorax. (68)Ga-DOTA-TATE and (123)I-MIBG detected a total of 30 lesions, of which 29/30 were positive with (68)Ga-DOTA-TATE and 7/30 with (123)I-MIBG. We also found higher incidence of SDHB positive results in patients with positive (68)Ga-DOTA-TATE.
Our limited data suggest that (68)Ga-DOTA-TATE is a better imaging agent for NCT and detects significantly more lesions with higher T/N ratio compared to (123)I-MIBG. (68)Ga-DOTA-TATE was more likely to detect malignant lesions as indicated by correlating imaging results with SDHB screening.
我们旨在比较(123)I-MIBG 和(68)Ga-DOTA-TATE 在神经嵴肿瘤(NCT)中的影像学表现,以观察后者是否能在发现更多病灶方面提供更多优势,并对恶性病灶具有更高的敏感性。
我们回顾性分析了 12 名患者(M=10,F=2;年龄范围 20-71 岁)的资料,这些患者均患有 NCT(嗜铬细胞瘤=7,副神经节瘤=4,甲状腺髓样癌=1),并在 6 个月内同时进行了(68)Ga-DOTA-TATE 正电子发射断层扫描(PET)或 PET/计算机断层扫描(CT)和(123)I-MIBG 单光子发射计算机断层扫描。对所有病灶进行了视觉评估,并对选定病灶进行了靶/非靶(T/N)比值的测量。5 名年龄在 50 岁或以下的患者进行了 SDHB 筛查,结果与两种放射性药物的影像学结果相关。所有患者均进行了增强 CT 和/或其他横断面成像。
在 12 例确诊疾病的患者中,(68)Ga-DOTA-TATE PET 显示 10 例患者有肿瘤病灶,而(123)I-MIBG 显示 5 例患者有肿瘤病灶。在 1 名患者中,(68)Ga-DOTA-TATE PET 和(123)I-MIBG 均为阴性,但 CT、磁共振成像和 2-脱氧-2-[[18]F]氟代葡萄糖 PET 扫描在胸部发现了病灶。(68)Ga-DOTA-TATE 和(123)I-MIBG 共检测到 30 个病灶,其中 29/30 个病灶在(68)Ga-DOTA-TATE 为阳性,7/30 个病灶在(123)I-MIBG 为阳性。我们还发现,(68)Ga-DOTA-TATE 阳性患者中 SDHB 阳性结果的发生率更高。
我们的有限数据表明,(68)Ga-DOTA-TATE 是一种更好的 NCT 影像学检查手段,与(123)I-MIBG 相比,它能更准确地检测到更多的病灶,并具有更高的 T/N 比值。(68)Ga-DOTA-TATE 更有可能通过与 SDHB 筛查结果相关联来检测恶性病灶。